Photo by Meritt Thomas on Unsplash
65a69c84e71de0001e7ec315 Sbt Uvc

UV-C technology eliminates 99.99% of airborne SARS-CoV-2 in HVAC

April 28, 2021
UltraViolet Devices, Inc. (UVDI) provides proven airstream protection – and peace-of-mind – for critical infrastructure globally such as airports, healthcare facilities, schools and government buildings.

UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.

The testing was conducted at Innovative Bioanalysis, a BEI-recognized BSL-3 laboratory in California. SARS-CoV-2 is the primary viral strain that causes the COVID-19 infection, which the Centers for Disease Control and Prevention (CDC) has indicated can be spread by both airborne and surface transmission.

In the independent testing, UVDI V-MAX UV-C air disinfection technology eliminated 99.99% of SARS-CoV-2 in a single pass at an airflow rate of 500 feet per minute.

To confirm effectiveness against airborne SARS-CoV-2 in a moving airstream, Innovative Bioanalysis used a HVAC duct test based on a modified ISO 15714 and ASHRAE 185.1 standard. To replicate conditions in a typical HVAC duct, UVDI V-MAX™ 254 nm UV-C lamps were arranged in a parallel configuration.

“This novel testing underlines UVDI’s UV-C technology’s effectiveness against airborne SARS-CoV-2,” stated Dr. Ashish Mathur, Ph.D., UVDI Vice President of Innovation and Technology.

Mathur added, “The study results are further evidence that UVDI provides proven airstream protection – and peace-of-mind – for critical infrastructure globally such as airports, healthcare facilities, schools and government buildings as well as for high-traffic public spaces such as arenas, sports facilities and hospitality sites.”

UVDI’s V-MAX UV-C air disinfection technology works by damaging the DNA of microorganisms, eliminating their ability to reproduce and infect people. UV-C air disinfection product effectiveness against coronavirus is currently supported using established models to estimate the UV-C dose required to inactivate the virus.

The BSL-3 laboratory results also confirm the accuracy of UVDI’s proprietary modelling software, which determines custom product configurations for targeted UV-C effectiveness. The software was used to inform the study’s protocols.

UVDI has the press release.

More Info:

https://www.uvdi.com/hvac/

https://www.uvdi.com/covid-19/

This article originally appeared at SBT's sister site, Healthcare Purchasing News.

Voice your opinion!

To join the conversation, and become an exclusive member of Buildings, create an account today!

Sponsored Recommendations